Britain and America have hammered out a landmark commercial pact that will preserve zero import taxes on British pharmaceutical shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on drugs through the NHS. This move secures that tariffs on these key products will be held at nothing for a period of three years.
This agreement comes after earlier warnings to dramatically increase tariffs on branded drug products, with increases discussed as high as 100%.
"This arrangement between the UK strengthens the international landscape for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," a release noted.
Commercial Impact
Pharmaceuticals are one of the Britain's largest export categories to the US, which is easily the primary destination for leading British pharmaceutical firms.
Export figures show that in the year leading up to the third quarter, the UK shipped medicines valued at over eleven billion pounds to the US. This figure represented nearly one-fifth of all goods exports in that timeframe.
"This agreement protects employment, increases capital expenditure and paves the way for the UK to become a international leader for medical research," a government official remarked.
Key NHS Changes
The pact involves several specific changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to raise total public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at 15%. In the past, refunds exceeded twenty percent.
Industry Background
The pact takes place against a protracted dispute between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were heightened by assertions that US customers were charged significantly more for the equivalent treatments than people in the other developed nations.
Recently, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
